ENDPOINTS NEWS23 天
Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u ...
A decade af­ter Keytru­da hit the mar­ket, Mer­ck has now said a sub­cu­ta­neous ver­sion of the im­munother­a­py passed a ...
BioSpace24 天
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met ...
The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ®, together with berahyaluronidase alfa ...